Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Renal Cell 23Glioblastoma 13Lymphoma, Mantle-Cell 10Endometrial Neoplasms 10Prostatic Neoplasms 9Neoplasms 9Breast Neoplasms 9Brain Neoplasms 9Neoplasm Metastasis 8Kidney Neoplasms 8Gliosarcoma 8Melanoma 7Sarcoma 6Lymphoma, Non-Hodgkin 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Oligodendroglioma 5Multiple Myeloma 5Lymphoma, Follicular 5Lymphoma 5Glioma 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Lymphoma, B-Cell, Marginal Zone 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Rhabdomyosarcoma 3Osteosarcoma 3

Interventions

Iodine-131 11Thyrotropin Alfa 9Sorafenib 8lenvatinib 6Thyroidectomy 6vandetanib 5Sunitinib 5Saline Solution 5pazopanib 4Triiodothyronine 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Vemurafenib 3Thyroxine 3Radiotherapy 3Everolimus 3Dexmedetomidine 3Control Groups 3Cisplatin 3AZD 6244 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3trametinib 2tipifarnib 2romidepsin 2dabrafenib 2belinostat 2Trastuzumab 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Immunohistochemistry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid Neoplasms × temsirolimus × Clear all
NCT01025453 2018-08-15

Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
37 enrolled 11 charts
Head & Neck

Thyroid Diseases, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡